Mn Services Vermogensbeheer B.V. Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mn Services Vermogensbeheer B.V. grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 93,660 shares of the medical equipment provider’s stock after acquiring an additional 1,700 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Hologic were worth $6,752,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its holdings in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after acquiring an additional 81,057 shares during the last quarter. FMR LLC raised its stake in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Hologic by 8.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after purchasing an additional 195,285 shares during the period. Finally, Nordea Investment Management AB raised its stake in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Trading Up 0.3 %

Shares of HOLX opened at $63.38 on Friday. The business’s 50-day moving average price is $69.16 and its 200-day moving average price is $75.94. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The stock has a market cap of $14.22 billion, a PE ratio of 19.99, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.